anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Carbon
Trial phase: Phase 4
ATC code: A07BA01 | A07BA51
SMILES: [C]
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 45
Group description: epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologists (ASA) I-II physical status,
aged 40-60 yr,
BMI 19-25 kg/m2,
undergoing elective gastrointestinal surgery

Exclusion Criteria:

patients with cardiovascular or neurological disease, drug or alcohol abuse and absolute contraindications for neuraxial blockade.
Intervention: Letrozole
Trial phase: Phase 4
ATC code: L02BG04
SMILES: N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1
Sex: Male
Age groups: Child
Healthy volunteers: No
Participants at risk: 39
Group description: Participants receive letrozole 2.5 mg daily
Eligibility criteria:
Inclusion Criteria:

Current height less than 5th percentile AND/OR
Predicted adult height (based on bone age) more than 10 cm below target height (mid parental height)
Evidence of puberty: physical signs and serum luteinizing hormone > 0.3 IU/L and testosterone > 15 ng/dl

Exclusion Criteria:

Bone age reading more than 14.0 years
Follicle stimulating hormone > 20 IU/L
Intervention: Anastrozole
Trial phase: Phase 4
ATC code: L02BG03
SMILES: CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1
Sex: Male
Age groups: Child
Healthy volunteers: No
Participants at risk: 40
Group description: Participants receive anastrozole 1 mg daily
Eligibility criteria:
Inclusion Criteria:

Current height less than 5th percentile AND/OR
Predicted adult height (based on bone age) more than 10 cm below target height (mid parental height)
Evidence of puberty: physical signs and serum luteinizing hormone > 0.3 IU/L and testosterone > 15 ng/dl

Exclusion Criteria:

Bone age reading more than 14.0 years
Follicle stimulating hormone > 20 IU/L
Intervention: Lubiprostone
Trial phase: Phase 3
ATC code: A06AX03
SMILES: [H][C@@]12CC(=O)[C@H](CCCCCCC(=O)O)[C@@]1([H])CC[C@](O)(C(F)(F)CCCC)O2
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 419
Group description: Participants receive lubiprostone
Eligibility criteria:
Inclusion Criteria:

Has completed the 3-month placebo-controlled study (NCT02042183)
Will continue to abstain from taking concomitant medication (prescribed or over-the-counter) that affects gastrointestinal motility

Exclusion Criteria:

Has untreated faecal impaction at the time of rolling over into study
Has significant change in medical status, newly diagnosed and uncontrolled cardiovascular, liver or lung disease, neurologic or psychiatric disorder, or other systemic disease
Has demonstrated non-compliance with study protocol during the 3-month placebo-controlled study (NCT02042183)
Intervention: ALENDRONIC ACID
Trial phase: Phase 4
ATC code: M05BA04 | M05BB03 | M05BB05 | M05BB06
SMILES: NCCCC(O)(P(=O)(O)O)P(=O)(O)O
Sex: Female
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Alendronate continuation arm

Alendronate
Eligibility criteria:
Inclusion Criteria:

1.Females 65+

2.3+ years of alendronate (Fosamax/Binosto) use

3. Valid social security number

Exclusion Criteria:

History of any other metabolic bone condition, such as Paget Disease of Bone
Currently receiving treatment for ongoing cancer, excluding non-melanoma skin cancer.
Has significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)?
HIV positive
Involved in a conflicting (investigational drug) clinical trial
Intervention: ALENDRONIC ACID
Trial phase: Phase 4
ATC code: M05BA04 | M05BB03 | M05BB05 | M05BB06
SMILES: NCCCC(O)(P(=O)(O)O)P(=O)(O)O
Sex: Female
Age groups: Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: Alendronate discontinuation arm

Alendronate
Eligibility criteria:
Inclusion Criteria:

1.Females 65+

2.3+ years of alendronate (Fosamax/Binosto) use

3. Valid social security number

Exclusion Criteria:

History of any other metabolic bone condition, such as Paget Disease of Bone
Currently receiving treatment for ongoing cancer, excluding non-melanoma skin cancer.
Has significant underlying illness that would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 3 years)?
HIV positive
Involved in a conflicting (investigational drug) clinical trial
Intervention: Cyclophosphamide
Trial phase: Phase 2
ATC code: L01AA01
SMILES: O=P1(N(CCCl)CCCl)NCCCO1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 1.5 gms/m(2).

Cyclophosphamide: Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
Eligibility criteria:
Inclusion Criteria:

All patients must have a pathologic diagnosis of one of the following malignancies:

Non-Hodgkin's Lymphoma, including B- and T-cell lymphoma Multiple Myeloma or another plasma cell dyscrasia (Waldenstrom, Amyloidosis)

The patient must be approved for transplant by the treating Transplant physician.
This must be the patient's FIRST mobilization attempt.
Patients are eligible if an autologous transplant is planned within approximately 12 months from the time of collection of cells.
Prior Treatment: No previous cytotoxic chemotherapy within 4 weeks prior to initiation of therapy. (This does not include immunomodulatory drugs (IMiDs), proteasome inhibitors, monoclonal antibodies or steroids.)
No radiation within 4 weeks of mobilization attempt.
Age >18, and < 75 years
No significant co-morbid medical or psychiatric illness that would significantly compromise the patient's clinical care and chances of survival.
Informed consent must be signed prior to the treatment. Patients must willingly consent after being informed of the procedure to be followed, the nature of the therapy, alternatives, potential benefits, side effects, risks and discomforts. (Human protection committee approval of this protocol and a consent form is required.)

Exclusion Criteria:

Medical, social, or psychological factors that would prevent the patient from receiving or cooperating with the full course of therapy.
Documented hypersensitivity to any of the drugs used in the protocol.
Intervention: Cyclophosphamide
Trial phase: Phase 2
ATC code: L01AA01
SMILES: O=P1(N(CCCl)CCCl)NCCCO1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Patients will receive intravenous mesna 15 minutes prior to cyclophosphamide and again at 4 and 8 hours afterwards. Each infusion will be given over 15 minutes. Oral mesna can be substituted for the two post-cyclophosphamide doses. Oral mesna will be administered at 2 and 6 hours after the start of cyclophosphamide. Cyclophosphamide will be administered intravenously over one hour at the dose of 3 gms/m(2).

Cyclophosphamide: Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
Eligibility criteria:
Inclusion Criteria:

All patients must have a pathologic diagnosis of one of the following malignancies:

Non-Hodgkin's Lymphoma, including B- and T-cell lymphoma Multiple Myeloma or another plasma cell dyscrasia (Waldenstrom, Amyloidosis)

The patient must be approved for transplant by the treating Transplant physician.
This must be the patient's FIRST mobilization attempt.
Patients are eligible if an autologous transplant is planned within approximately 12 months from the time of collection of cells.
Prior Treatment: No previous cytotoxic chemotherapy within 4 weeks prior to initiation of therapy. (This does not include immunomodulatory drugs (IMiDs), proteasome inhibitors, monoclonal antibodies or steroids.)
No radiation within 4 weeks of mobilization attempt.
Age >18, and < 75 years
No significant co-morbid medical or psychiatric illness that would significantly compromise the patient's clinical care and chances of survival.
Informed consent must be signed prior to the treatment. Patients must willingly consent after being informed of the procedure to be followed, the nature of the therapy, alternatives, potential benefits, side effects, risks and discomforts. (Human protection committee approval of this protocol and a consent form is required.)

Exclusion Criteria:

Medical, social, or psychological factors that would prevent the patient from receiving or cooperating with the full course of therapy.
Documented hypersensitivity to any of the drugs used in the protocol.
Intervention: Ropivacaine
Trial phase: Phase 1
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 110
Group description: 30ml ropivacaine 0.125%

ropivacaine: Different concentration of ropivacaine
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologist physical status I-III patients
aged 18-70 yr
weighing 40-80 kg

Exclusion Criteria:

infection at the site of needle insertion
coagulopathy
international normalized ratio >1.4
platelet count <80×109 litre-1
allergy to local anaesthetics
peripheral neurological disease
peripheral vascular disease
patients do not agree to sign the informed consent.
Intervention: Ropivacaine
Trial phase: Phase 1
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 110
Group description: 30ml ropivacaine 0.2%

ropivacaine: Different concentration of ropivacaine
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologist physical status I-III patients
aged 18-70 yr
weighing 40-80 kg

Exclusion Criteria:

infection at the site of needle insertion
coagulopathy
international normalized ratio >1.4
platelet count <80×109 litre-1
allergy to local anaesthetics
peripheral neurological disease
peripheral vascular disease
patients do not agree to sign the informed consent.
Intervention: Ropivacaine
Trial phase: Phase 1
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 110
Group description: 30ml ropivacaine 0.25%

ropivacaine: Different concentration of ropivacaine
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologist physical status I-III patients
aged 18-70 yr
weighing 40-80 kg

Exclusion Criteria:

infection at the site of needle insertion
coagulopathy
international normalized ratio >1.4
platelet count <80×109 litre-1
allergy to local anaesthetics
peripheral neurological disease
peripheral vascular disease
patients do not agree to sign the informed consent.
Intervention: Ropivacaine
Trial phase: Phase 1
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 110
Group description: 30ml ropivacaine 0.375%

ropivacaine: Different concentration of ropivacaine
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologist physical status I-III patients
aged 18-70 yr
weighing 40-80 kg

Exclusion Criteria:

infection at the site of needle insertion
coagulopathy
international normalized ratio >1.4
platelet count <80×109 litre-1
allergy to local anaesthetics
peripheral neurological disease
peripheral vascular disease
patients do not agree to sign the informed consent.
Intervention: Ropivacaine
Trial phase: Phase 1
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 110
Group description: 30ml ropivacaine 0.5%

ropivacaine: Different concentration of ropivacaine
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologist physical status I-III patients
aged 18-70 yr
weighing 40-80 kg

Exclusion Criteria:

infection at the site of needle insertion
coagulopathy
international normalized ratio >1.4
platelet count <80×109 litre-1
allergy to local anaesthetics
peripheral neurological disease
peripheral vascular disease
patients do not agree to sign the informed consent.
Intervention: Ropivacaine
Trial phase: Phase 1
ATC code: N01BB09
SMILES: CCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 110
Group description: 30ml ropivacaine 0.75%

ropivacaine: Different concentration of ropivacaine
Eligibility criteria:
Inclusion Criteria:

American Society of Anesthesiologist physical status I-III patients
aged 18-70 yr
weighing 40-80 kg

Exclusion Criteria:

infection at the site of needle insertion
coagulopathy
international normalized ratio >1.4
platelet count <80×109 litre-1
allergy to local anaesthetics
peripheral neurological disease
peripheral vascular disease
patients do not agree to sign the informed consent.
Intervention: Colchicine
Trial phase: Phase 4
ATC code: M04AC01
SMILES: COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Baseline blood draw followed by colchicine followed by blood draw 2 hours and 24 hours later

Colchicine: Colchicine 1.2 mg followed by 0.6 mg one hour later
Eligibility criteria:
Inclusion Criteria:

Subjects must be more than 18 years of age

Exclusion Criteria:

1) history of cardiovascular disease, including myocardial infarction, history of percutaneous coronary angioplasty or stent, peripheral vascular disease or stroke; 2) history of myelodysplasia; 3) medications known to affect platelet function, including non-steroidal anti-inflammatory drugs, antihistamines, and selective serotonin reuptake inhibitors, during the 5 days prior to participation; 4) medications known to interact with colchicine; 5) history of intolerance to colchicine; 6) acute or chronic symptoms of diarrhea, nausea, or vomiting within 1 month prior to enrollment; 7) known anemia or hemoglobin <10mg/dL; 8) platelet count <100,000 or > 450,000; 9) creatinine clearance <30cc/minute; 10) any known hemorrhagic diathesis; 11) pregnant; 12) Unable to consent; or 13) Participating in a competing study.
Intervention: Linolenic Acid
Trial phase: Phase 4
SMILES: CCC=CCC=CCC=CCCCCCCCC(=O)O
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 34
Group description: Subjects will continue to take the clozapine prescribed as standard of care. Subjects assigned to added fish oil will receive OmegaBrite 500 mg gel cap BID days 1-7, and 1000 mg BID days 8-28 with breakfast and supper. Patients unable to tolerate the dose escalation to 1000 mg BID will have the fish oil dose reduce to 500 mg BID.

Fish Oil
Eligibility criteria:
Inclusion Criteria:

male or female patients with clinical diagnoses of schizophrenia or schizo-affective disorder
between 18 and 60 years of age
patients whose treating clinicians have recommended treatment with clozapine (and the patients have agreed and provided signed informed consent for treatment with clozapine)

Exclusion Criteria:

patients who have contraindications to metformin use, such as:

a diagnosis of congestive heart failure
renal impairment (serum creatinine > 1.5 in males; > 1.4 in females)
hepatic disease (AST or ALT > 2.0 times upper limit of normal (ULN)
positive hepatitis B surface antigen or hepatitis C antibody
total bilirubin>1.2x ULN; majority conjugated
metabolic acidosis (serum CO2 < lower limit of normal),
known hypersensitivity to metformin,
recent (in the past 30 days) or scheduled radiological studies involving iodinated contrast material
alcohol abuse/dependence within the past month
concurrent treatment with drugs that are known to increase metformin blood levels including furosemide, nifedipine, and cationic drugs including cimetidine, amiloride, digoxin, morphine, procainamide, quinidine, ranitidine, triamterene, trimethoprim, and vancomycin
patients with blood dyscrasias that could be worsened by added fish oil
women who are pregnant or breastfeeding
Intervention: Ibuprofen
Trial phase: Not Applicable
ATC code: C01EB16 | G02CC01 | M01AE01 | M01AE14 | M01AE51 | M02AA13 | N02AJ08 | N02AJ19 | R02AX02
SMILES: CC(C)Cc1ccc(C(C)C(=O)O)cc1
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 51
Group description: 10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal

Ibuprofen: 10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
Eligibility criteria:
Inclusion Criteria:

ages 4-17
unilateral ureteral stent placed after ureteropelvic junction obstruction repair or treatment of upper tract urolithiasis

Exclusion Criteria:

bilateral stents
undergoing other concomitant procedure at time of planned ureteral stent removal
indication for stent other than ureteropelvic junction obstruction repair or treatment of upper tract urolithiasis
pregnant
developmental delay
allergy to ibuprofen or non-steroidal anti-inflammatory medication class
chronic kidney disease
prior renal transplant
history of nasal polyps
history of asthma
Intervention: Olorofim
Trial phase: Phase 1
SMILES: Cc1cc(-c2ccccc2)c(C(=O)C(=O)Nc2ccc(N3CCN(c4ncc(F)cn4)CC3)cc2)n1C
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 6
Group description: Single intravenous infusion over 4 hours

F901318: Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.

Pharmacokinetic profile
Eligibility criteria:
Inclusion Criteria:

Subjects will be males of any ethnic origin between 18 and 45 years of age and weighing 60-90 kg inclusive
Subjects must be in good health, as determined by a medical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations (congenital non haemolytic hyperbilirubinaemia is acceptable)
Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions

Exclusion Criteria:

Male subjects who are not, or whose partners are not willing to use appropriate contraception (such as a condom) with established use of oral, injected or implanted hormonal contraceptive, intrauterine device or diaphragm with spermicide for three months after the last dose
Subjects who have received any prescribed systemic or topical medication within 14 days of dosing with study drug unless in the opinion of the Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety
Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days of dosing with study drug (with the exception of vitamin/mineral supplements) unless in the opinion of the Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety
Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of dosing with study drug unless in the opinion of the Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety
Subjects who are still participating in a clinical study (e.g. attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical or biological entity) in the past 3 months
Intervention: Famotidine
Trial phase: Phase 2
ATC code: A02BA03 | A02BA53
SMILES: NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
Eligibility criteria:
Inclusion Criteria:

Subjects with age ≥18 years and ≤80 years at the time of screening.
All Ischemic stroke patients with clinical and or radiological diagnosis.
Subjects who have presented to hospital within 6 hours of symptom onset.
The subject or his/ her legal representative is willing to undergo informed consent process prior to enrollment into this study.

Exclusion Criteria:

Subject with age < 18 years and >80 years at the time of screening.
Time of symptom onset cannot be determined.
Subject who is pregnant or lactating.
Subject who has asthma exacerbations in past 3 months.
Subject who has hypersensitivity to dextromethorphan, diphenhydramine or famotidine, or other H2 antagonists or any component of the formulation.
Serotonin syndrome.
Concurrent administration with or within 2 weeks of discontinuing an MAO inhibitor
Subjects with renal or hepatic failure.
The subject or legal representative is unable to provide informed consent.
The subject is medically unstable to participate in the trial as determined by the principal investigator.
The subject has any end stage medical condition as determined by the principal investigator.
Intervention: Pantoprazole
Trial phase: Phase 2
ATC code: A02BC02 | A02BD04 | A02BD11
SMILES: COc1ccnc(CS(=O)c2nc3ccc(OC(F)F)cc3[nH]2)c1OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care
Eligibility criteria:
Inclusion Criteria:

Subjects with age ≥18 years and ≤80 years at the time of screening.
All Ischemic stroke patients with clinical and or radiological diagnosis.
Subjects who have presented to hospital within 6 hours of symptom onset.
The subject or his/ her legal representative is willing to undergo informed consent process prior to enrollment into this study.

Exclusion Criteria:

Subject with age < 18 years and >80 years at the time of screening.
Time of symptom onset cannot be determined.
Subject who is pregnant or lactating.
Subject who has asthma exacerbations in past 3 months.
Subject who has hypersensitivity to dextromethorphan, diphenhydramine or famotidine, or other H2 antagonists or any component of the formulation.
Serotonin syndrome.
Concurrent administration with or within 2 weeks of discontinuing an MAO inhibitor
Subjects with renal or hepatic failure.
The subject or legal representative is unable to provide informed consent.
The subject is medically unstable to participate in the trial as determined by the principal investigator.
The subject has any end stage medical condition as determined by the principal investigator.